Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Key facts
- Who runs it
- Dompé Farmaceutici S.p.A
- Where
- Atlanta, Augusta, Beaumont, Boston, Brooklyn, Charlottesville, Chicago, Clearwater, Columbia, Denison, Denver, Durham, Gary, Jacksonville, Knoxville, Midland, New York, Newton, Orange, Philadelphia, Portland, Richmond, Royal Oak, Salt Lake City, St Louis, Tucson, and Washington D.C., United StatesSee the 28 sitesAlso in 6 other countries, 46 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 414 people enrolled
- Started
- 27 Apr 2022
- Ended
- 27 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Reparixin
- Placebo
- Record updated
- 24 February 2026
- Why it stopped
- The study was stopped due to futility as per protocol
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Informed consent signed
- Male and female ≥18 years old
- Patients hospitalized for clinically suspected CAP, defined as the occurrence of (within 48h from hospital admission):; at least 1 of the following signs/symptoms: dyspnea, cough, purulent sputum, crackles (rales) and/or rhonchi; body temperature > 38°C or <36°C (before or during admission) or leucocytosis (> local ULN); new/increased pulmonary infiltrate(s) by chest imaging
- Need for non-invasive supplemental oxygen (NIAID-OS 5-6)
- SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300
- Females of child-bearing potential and with an active sexual life must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:; Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last IMP dose; A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last IMP dose; A male sexual partner who agrees to use a male condom with spermicide; A sterile sexual partner; Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, with child-bearing potential, pregnancy test result must be negative before first drug intake
Who cannot take part
- Treatment with IMV or ECMO (NIAID-OS 7)
- Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
- Active bleeding or bleeding diathesis (excluding menses), prior intracranial haemorrhage
- Pregnancy:; positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
- Clinical condition not compatible with oral administration of the study drug
- Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
- Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score B or C)
- Renal dysfunction: estimated glomerular filtration rate (eGFR, MDRD) <50 mL/min/1.73 m2, or need for haemodialysis or hemofiltration
- Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anaemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
- History of:; intolerance or hypersensitivity to ibuprofen to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib (hypersensitivity to sulphanilamide antibiotics alone, e.g. sulfamethoxazole does not qualify for exclusion); lactase deficiency, galactosemia or glucose-galactose malabsorption; gastrointestinal bleeding or perforation due to previous NSAIDs therapy or recurrent peptic ulcer/haemorrhage; allergy to reparixin or any component of the IMP formulation
- Anticipated discharge from the hospital or transfer to another hospital within 72 hours of screening
- Participation in other interventional clinical trials
- Current hospital stay >72h
Where in United States
Also in 6 other countries, 46 sites
- Emory Johns Creek HospitalAtlanta, United States
- Augusta University Health - Augusta University Medical CenterAugusta, United States
- Baptist Hospitals of Southeast TexasBeaumont, United States
- Beth Israel Deaconess Medical CenterBoston, United States
- NYU Langone Hospital - BrooklynBrooklyn, United States
- University of Virginia Medical CenterCharlottesville, United States
- Northwestern University Feinberg School of MedicineChicago, United States
- Research Alliance Inc.Clearwater, United States
- University Hospital - MU HealthcareColumbia, United States
- Texoma Medical CenterDenison, United States
- Denver HealthDenver, United States
- Duke University HospitalDurham, United States
- Methodist HospitalGary, United States
- University of Florida - JacksonvilleJacksonville, United States
- University of Tennessee Medical CenterKnoxville, United States
- MidMichigan Medical Center MidlandMidland, United States
- New York University Langone HealthNew York, United States
- Newton-Wellesley HospitalNewton, United States
- UCI HealthOrange, United States
- Jefferson University HospitalPhiladelphia, United States
- Oregon Health & Science University (OHSU) - Pulmonary ClinicPortland, United States
- Virginia Commonwealth University HealthRichmond, United States
- William Beaumont HospitalRoyal Oak, United States
- University of Utah Hospitals & ClinicsSalt Lake City, United States
- Mercy Research - St. LouisSt Louis, United States
- Washington University School of MedicineSt Louis, United States
- MD Banner University Medical Center /Arizona UniversityTucson, United States
- MedStar Health Research Institute-Hyatteville, MarylandWashington D.C., United States
About the trial
What the trial wants to find out
Primary objective:
Read full original descriptionShow less
- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
Key secondary objectives:
* To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs placebo in proportion of patients alive and discharged at day 28 * To compare the efficacy of reparixin vs placebo in ventilatory-free days at day 28. * To compare the efficacy of reparixin vs placebo in proportion of patients with IMV (or ECMO) by day 28. * To compare the efficacy of reparixin vs placebo in length of primary hospital stay.
Other efficacy objectives
- To compare the efficacy of reparixin vs placebo on several disease severity/progression measures including recovery, ventilatory free days and mortality.
Safety objectives:
- To evaluate safety and tolerability of oral reparixin versus placebo in the specific clinical setting.
The 2 groups in the trial
- Reparixin + standard of care (SoC)Treatment being tested
Reparixin was administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days. The three daily doses were administered maintaining an interval between doses of about 8 hours.
Treatment: Reparixin
- Placebo + standard of care (SoC)Placebo, for comparison
Placebo tablets are identical in appearance to the active formulation. Placebo was administered with the same treatment schedule.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
- Record updated
- 24 February 2026